Growth hormone therapy in GH-deficient adults: continuous vs alternate-days treatment.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a controlled clinical trial.

Measurements included: IGF-I levels, body composition (BF%), lipid profile, insulin sensitivity by homeostasis model assessment (HOMA-IR) and quantitative insulin check index (QUICKI), as well as thyroid function.

Evaluation on A therapy was performed both 12 and 36 hours after the last rhGH injection.

Who Took Part

The study group was 20 subjects.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

What Was Measured

Measurements included: IGF-I levels, body composition (BF%), lipid profile, insulin sensitivity by homeostasis model assessment (HOMA-IR) and quantitative insulin check index (QUICKI), as well as thyroid function.

Evaluation on A therapy was performed both 12 and 36 hours after the last rhGH injection.

Topics PubMed links to this paper include Body Composition, Growth Hormone, Hormone Replacement Therapy, Human Growth Hormone, Insulin, Insulin-Like Growth Factor I and Lipids.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 20 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2003 (Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.